Dr. Baskies is a specialist in surgical oncology and general surgery, affiliated with Virtua Health Systems. He is former Chairman of the National Board of Directors of the American Cancer Society and current Chair of the society’s Global Cancer Control Advisory Council. He is a member of the Global Breast ...
Dr. Budd is a specialist in breast cancer and the principal investigator of the Cleveland Clinic and Anixa partnered Phase 1 trial of the Breast Cancer Vaccine. He is Professor of Medicine in the Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Cancer Center, and Professor in the ...
Dr. Leyland-Jones is a pre-eminent clinical trialist in oncology and the recipient of numerous awards. He is the Chief Medical Officer of AIM-HI Accelerator Fund, OTraces, and the N OF 1 Mission. In addition, he is a Scientific Advisory Board Member of the National Foundation for Cancer Research and NED ...
Dr. Rugo is a leader and specialist in breast cancer research and recipient of numerous awards. She is Professor, Department of Medicine (Hematology/Oncology), and Director, Breast Oncology and Clinical Trials Education, at the UCSF Helen Diller Family Comprehensive Cancer Center. She is Co-chair of the Triple Negative Working Group, a member ...
Dr. Schoenberger is a translational immunologist working in the area of precision cancer immunotherapy. He is a professor in the Center for Cancer Immunotherapy at the La Jolla institute for Immunology and Adjunct Professor of Medicine in the Division of Hematology and Oncology at the UC San Diego Moores Cancer ...
Latest News & Events
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Read More...Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Read More...Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Read More...